• AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications.
• Powered by innovative SBX technology, the platform is capable of end-to-end, same-day whole-genome sequencing in research workflows, with accurate results within hours.
• The AXELIOS 1 platform holds promise for research laboratories today, and potentially for a broad range of clinical settings in the future.

Roche (SIX: RO, ROP; OTCQX: RHHBY) announced the launch of AXELIOS 1 based on the innovative SBX technology, with a unique combination of accuracy, speed, flexibility, scalability and cost efficiency that addresses critical bottlenecks in genomics and potentially in clinical research. AXELIOS 1 will enable researchers to make significant discoveries that enhance our understanding of diseases, with the potential to replace existing technologies in pivotal research areas.

“AXELIOS 1 will deliver a disruptive sequencing solution that combines high accuracy with unprecedented speed and scalability. These attributes, combined with our high level of cost efficiency, will enable the sequencing community to develop applications that previously were not feasible,” said Matt Sause, CEO of Roche Diagnostics. “Additionally, in the future, AXELIOS 1 has the same potential to enable the next generation of clinical applications and unlock new frontiers in personalised healthcare.”

The AXELIOS 1 platform’s flexible sequencing run setup and high-throughput effortlessly handle everything from small-scale studies to massive genomic projects, ensuring laboratories can expand their research capabilities with a single instrument.  For researchers, this flexible and open setup grants broader freedom of exploration and new workflows that can truly expand our knowledge of complex diseases.

Through collaborations with leading institutions, such as Hartwig Medical Foundation and Broad Clinical Labs, AXELIOS 1 launches with proven real-world capabilities, including studies that confirm the AXELIOS 1 platform delivers impressive accuracy and throughput with record-breaking speed and better cost efficiency.¹ These collaborations also extend to library preparation and analysis tools, including a partnership with 10x Genomics for single-cell and spatial application kits, and support for SBX via Google DeepVariant as well as the open-source suite of XOOS tools.

With a market value of USD 7.3 billion², sequencing continues to expand across both research and clinical sectors and overall growth is projected to reach double digits within the next few years. Since sharing early access data last and earlier this year, there has been strong interest in the SBX technology from the sequencing community.